Core Insights - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to develop innovative small molecule medicines [2][1] - The company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET, with a live webcast available on its website [1] Company Overview - Kymera Therapeutics is pioneering TPD to address critical health issues and improve patient outcomes, having advanced the first degrader into clinical trials for immunological diseases [2] - The company aims to deliver oral small molecule degraders as a new generation of effective therapies for patients, while also developing oncology programs targeting undrugged or poorly drugged proteins [2] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [2]

BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual UBS Targeted Protein Degradation Day on Monday, July 15, 2024, at 3:30 p.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.mo ...

Group 1: UBS and Credit Suisse Merger - UBS Group AG has completed the merger of UBS Switzerland AG and Credit Suisse (Schweiz) AG, marking a significant step in the integration process [1] - Following the merger, Credit Suisse (Schweiz) AG has been deregistered, and UBS Switzerland AG now holds all rights and obligations of Credit Suisse (Schweiz) AG [1] - The merger simplifies the transition for clients and operations, with Credit Suisse clients now becoming clients of UBS Switzerland AG while continuing to use existing platforms [1] Group 2: Client Transition and Cost Reduction Plans - The majority of client transactions in Switzerland will migrate to the UBS platform by 2025, with a gradual approach and tailored updates for clients [2] - UBS Group plans to wind down its Non-Core and Legacy portfolio, aiming to release over $6 billion in capital by the end of 2026 and achieve gross cost reductions of around $13 billion compared to 2022 levels [2] - The bank has already realized $1 billion in gross cost savings in Q1 2024 and targets an additional $1.5 billion in savings by the end of 2024 [2] Group 3: Market Performance and Future Plans - The merger of UBS Group AG and Credit Suisse AG was finalized on May 31, 2024, with a transition to a single U.S. intermediate holding company planned for Q2 2024 [3] - This transition is expected to enhance UBS's capabilities in wealth and asset management and support the growth of capital-light businesses [3] - UBS Group's shares have increased by 0.8% on the NYSE over the past six months, while the industry has seen a growth of 6.6% [3]

Group 1: UBS Group AG Developments - UBS Group AG is re-aligning its wealth-management business to enhance offerings for ultra-rich clients, with a new division called GWM Solutions set to launch on July 1, 2024 [1] - GWM Solutions will consolidate various products, including investment management, lending, family and institutional wealth management, and alternative investments, managed by Yves-Alain Sommerhalder [1] - UBS is also establishing a unit named Unified Global Alternatives to integrate alternative asset-management products with its wealth business [2] Group 2: Financial Performance and Restructuring - Wealth management constitutes over 50% of UBS Group's total revenues, highlighting its significance as the bank's flagship business [2] - UBS plans to release over $6 billion of capital by the end of 2026 by winding down non-core and legacy portfolios, aiming for gross cost reductions of approximately $13 billion compared to 2022 levels [2] - UBS shares have decreased by 4.7% on the NYSE over the past six months, contrasting with the industry's growth of 0.8% [4] Group 3: Industry Trends - Other banks, such as AssetMark Financial Holdings Inc. and Citizens Financial Group, are also restructuring their wealth management businesses to attract high-net-worth clients [5][6] - AssetMark is acquiring approximately $12 billion in assets from Morningstar Wealth as part of a strategic coalition, expected to close in the second half of 2024 [5] - Citizens Financial Group is focusing on growth in wealth management offerings and enhancing capabilities in the high-net-worth segment [6]

UBS Group AG (UBS) is asking the Swiss authorities to clarify how much additional the bank will need to hold in capital buffers after acquiring Credit Suisse. Investors are concerned that the negotiations could be delayed for months.The sources stated that some top executives at the bank had been relieved by the government's 'too-big-to-fail' recommendations released in April, which were unexpectedly flexible and modest following Credit Suisse's collapse.Concerns have been raised, nevertheless, after Stefan ...

Anheuser-Busch InBev stock still looks too expensive to buy.Anheuser-Busch InBev (BUD 3.05%) stock rose 2.8% through 12:05 p.m. ET on Monday after UBS analyst Sanjeet Aujla upgraded shares of the beer giant to buy, and raised its price target to 72 euros (about $77.30).Previously, Aujla had a neutral rating on the stock, and a price target of 62.5 euros (about $67.10).What UBS says about Anheuser-BuschThe analyst likes three things about Anheuser-Busch stock: growth, profit margins, and cash returns, as des ...

UBS Group AG (UBS) announced that Credit Suisse Supply Chain Finance Funds have made an offer to redeem fund units. The company will return 90% of the money invested in Credit Suisse funds linked to the collapse of Greensill Capital. This is part of the effort being undertaken by the Swiss bank to resolve Credit Suisse's difficulties.Investors in the Credit Suisse Supply Chain Finance Funds may choose to redeem 90% of the net asset value determined on Feb 25, 2021. The offer commenced on Jun 17, 2024, and w ...

UBS Group AG (UBS) has started final negotiations with a Beijing-backed fund to divest its China brokerage venture of Credit Suisse as talks with Citadel Securities LLC stalled. This news was reported by Bloomberg, citing people familiar with the matter.Beijing State-Owned Assets Management Co. (“BSAM”), Credit Suisse's Chinese partner - Founder Securities, and UBS Group are now having exclusive talks over the acquisition. By the end of this month, a decision and agreement with the buyer might be achieved.A ...

A group of Credit Suisse bondholders filed a lawsuit against the Swiss government, seeking full compensation over the contentious decision to write down the failed bank's Additional Tier 1 (AT1) debt.As part of Credit Suisse's emergency sale to UBS last year, which was orchestrated by the Swiss government, Swiss regulator Finma wiped out roughly $17 billion of the bank's AT1s, writing them down to to zero.The bank's common shareholders received payouts when the sale was completed.The move angered bondholder ...

A month has gone by since the last earnings report for UBS (UBS) . Shares have added about 8.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is UBS due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. UBS Group Q1 Earnings & Revenues Jump Y/Y, Expenses RiseUBS Group AG r ...